03/05/2023 - INVIVO PARTNERS
PORTFOLIO NEWS: Congratulations to ARTHEx Biotech for successfully closing a €42M Series B financing round to advance their novel treatment for Myotonic Dystrophy Type 1 (DM1). We are proud to have been their first investor, discovering the company in 2019.
02/02/2023 - INVIVO PARTNERS
JOB OPPORTUNITY / INTERNSHIP PROGRAM: We're seeking candidates to join us. Apply now!
31/01/2023 - INVIVO PARTNERS
We are excited to announce that Claudio Santos has joined us as Entrepreneur in Residence to support our company creation activity in the technology transfer space
17/01/2023 - INVIVO PARTNERS
JOB OPPORTUNITY: Our portfolio company Telomere Therapeutics is seeking candidates for a Project Manager position.
20/09/2022 - INVIVO CAPITAL
We’re pleased to announce our second exit in less than a year: Genfit has announced it will acquire Versantis.
04/07/2022 - EXPANSIÓN
Investing In Leading-Edge. Article published today in Expansión with the participation of Luis Pareras.
10/06/2022 - INVIVO CAPITAL
JOB OPPORTUNITY: We’re seeking candidates with a strong scientific background to join our #internship opportunity. If you’re interested in learning how a #VC firm works, please apply!
25/04/2022 - INVIVO CAPITAL
JOB OPPORTUNITY: We are looking for Controller candidates. If you are interested, please apply!
30/03/2022 - INVIVO CAPITAL
Integra Therapeutics completes the €6-million seed round with the addition of Columbus Venture Partners
09/12/2021 - INVIVO CAPITAL
Invivo Capital invests together with Kurma Partners, V-Bio Ventures and Omnes Capital in Corteria Pharmaceuticals, a French biotechnology company developing novel therapies for heart failure subpopulations with a high unmet clinical need.
02/12/2021 - INVIVO CAPITAL
Integra Tx secures €4.5-million in funding from Invivo Capital, Advent France Biotechnology and Takeda Ventures
22/11/2021 - INVIVO CAPITAL
Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology
12/03/2021 - AJUNTAMENT DE BARCELONA
L’Ajuntament de Barcelona ha seleccionat Invivo Ventures FCR junt amb altres 5 fons de capital risc privats per participar en la iniciativa Barcelona Accelera
16/12/2020 - Expansión (Ed. Cataluña)
Peptomyc capta 11,4 millones para iniciar un ensayo clínico en cáncer
16/12/2020 - Minoryx Therapeutics
Minoryx’s clinical candidate leriglitazone shows clinical benefit in a proof of concept Phase 2 study in Friedreich´s ataxia
01/12/2020 - INVIVO CAPITAL
Invivo boosts a gene therapy startup, Telomere Therapeutics, with 1.5 million
23/07/2020 - INVIVO CAPITAL
Arthex secures €4.25M from Invivo Ventures and Advent France Biotechnology
20/07/2020 - WEB CAPITAL RIESGO
Invivo Ventures, CDTI-Innvierte y la Fundación Josep Carreras cierran una ronda de €3,05 millones en OneChain Immunotherapeutics.
20/07/2020 - CAPITAL RIESGO
Invivo Ventures, CDTI-Innvierte y la Fundación Josep Carreras cierran una ronda de financiación de 3.050.000€ en OneChain Immunotherapeutics
20/07/2020 - INVIVO CAPITAL
The Josep Carreras Institute creates a spin-off to develop therapies for leukaemia based on CAR–T
13/07/2020 - INVIVO CAPITAL
Telum Therapeutics raises € 4.1 million in its first round of financing to advance the development of new synthetic biology-based therapies for the treatment of infectious diseases caused by multi-resistant bacteria.
13/07/2020 - PLANTA DOCE
Telum Therapeutics cierra una ronda de 4,1 millones liderada por Invivo Ventures
26/05/2020 - INVIVO CAPITAL
A new cancer immune therapy spin-off of Hospital Clínic-IDIBAPS (Barcelona) secures a 1.5 million-euro investment from Invivo Ventures
14/04/2020 - Invivo Capital
Barcelona-based synthetic biology company secures two-million-euro investment
14/04/2020 - Planta Doce
Invivo Ventures impulsa Pulmobiotics con una ‘inyección’ inicial de dos millones de euros
08/01/2020 - PlantaDoce
Invivo Ventures lidera una ronda de financiación de 1,5 millones en Arthex Biotech
08/01/2020 - Expansión Cataluña
El fondo Invivo Ventures debuta con una ronda de 1,5 millones en Arthex Biotech
29/03/2019 - INVIVO CAPITAL